Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) Announces Quarterly Earnings Results, Beats Expectations By $0.18 EPS

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY) released its quarterly earnings data on Monday. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18, Zacks reports. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 41.08% and a return on equity of 13.56%.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

SGIOY stock opened at $9.04 on Monday. Shionogi & Co., Ltd. Unsponsored ADR has a 52 week low of $7.65 and a 52 week high of $12.00. The company has a market cap of $15.39 billion, a P/E ratio of 11.30, a P/E/G ratio of 3.55 and a beta of 0.09. The company’s 50-day moving average price is $8.82 and its 200 day moving average price is $9.88. The company has a current ratio of 1.58, a quick ratio of 1.46 and a debt-to-equity ratio of 0.01.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on SGIOY shares. Zacks Research upgraded Shionogi & Co., Ltd. Unsponsored ADR from a “strong sell” rating to a “hold” rating in a research note on Monday, May 25th. Jefferies Financial Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 14th. Finally, The Goldman Sachs Group upgraded shares of Shionogi & Co., Ltd. Unsponsored ADR from a “hold” rating to a “strong-buy” rating in a research report on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating and one has issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy”.

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japan-based pharmaceutical company that conducts research, development, manufacturing and marketing of prescription drugs and vaccines. Established in the late 19th century, the company has expanded its focus beyond domestic markets to become a global player in pharmaceuticals, with particular expertise in anti-infectives, pain management, cardiovascular and central nervous system disorders.

The company’s product portfolio spans both established and innovative therapies.